Closely Related Mycobacterial Strains Demonstrate Contrasting Levels of Efficacy as Antitumor Vaccines and Are Processed for Major Histocompatibility Complex Class I Presentation by Multiple Routes in Dendritic Cells
- 1 February 2005
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (2) , 784-794
Abstract
Mycobacteria expressing recombinant antigens are already being developed as vaccines against both infections and tumors. Little is known about how dendritic cells might process such antigens. Two different mycobacterial species, the fast-growingMycobacterium smegmatisand the slow-growingM. bovis M. bovisBCG, were engineered to express a model tumor antigen, the Kb-restricted dominant cytotoxic T-lymphocyte epitope OVA257-264. RecombinantM. bovisBCG but not recombinantM. smegmatisconferred protection to mice challenged with the B16-OVA tumor cell line. We went on to investigate whether the contrast in antitumor efficacy could be due to differences in how dendritic cells process antigen from the two mycobacterial strains for class I presentation. Both strains of mycobacteria caused phenotypic maturation of dendritic cells, but recombinantM. smegmatisinfection led to a greater degree of dendritic cell maturation than recombinantM. bovisBCG infection. Antigen from recombinantM. smegmatiswas processed and presented as OVA257-264on Kbmolecules by the dendritic cell line DC2.4 but not by bone marrow-derived dendritic cells (BMDC) or splenic dendritic cells. In contrast, antigen from recombinantM. bovisBCG was presented by all three dendritic cell types as long as the mycobacteria were viable. Such presentation was dependent on proteasome function and nascent major histocompatibility complex (MHC) class I molecules in DC2.4 cells but independent of the proteasome and transporter associated with antigen processings (TAP) in BMDC and splenic dendritic cells. These data demonstrate for the first time that antigen vectored by the slow-growingM. bovisBCG but not that vectored by fast-growing, readily destroyedM. smegmatisis processed and presented on MHC class I by in vitro-generated dendritic cells, which has implications for recombinant microbial vaccine development.Keywords
This publication has 55 references indexed in Scilit:
- A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapyGene Therapy, 2002
- Bugs as drugs for cancerImmunology, 2002
- Endoplasmic Reticulum-Mediated Phagocytosis Is a Mechanism of Entry into MacrophagesCell, 2002
- Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunityMolecular Immunology, 2000
- MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSINGAnnual Review of Immunology, 1998
- MHC Class I–Restricted CTL Responses to Exogenous AntigensImmunity, 1996
- A new foreign policy: MHC class I molecules monitor the outside worldImmunology Today, 1996
- Phagocytic processing of bacterial antigens for class I MHC presentation to T cellsNature, 1993
- Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccinesNature, 1991
- Introduction of soluble protein into the class I pathway of antigen processing and presentationCell, 1988